Four Different Regimens of Farnesyltransferase Inhibitor Tipifarnib in Older, Untreated Acute Myeloid Leukemia Patients: North American Intergroup Phase II Study SWOG S0432

Overview

Journal Leuk Res

Date 2014 Jan 14

PMID 24411921

Citations 10

Authors

Harry P Erba

Megan Othus

Roland B Walter

Mark H Kirschbaum

Martin S Tallman

Richard A Larson

Marilyn L Slovak

Kenneth J Kopecky

Holly M Gundacker

Frederick R Appelbaum

Affiliations

Soon will be listed here.

Abstract

We report on 348 patients ≥ 70 years (median age 78 years) with acute myeloid leukemia (>50% with secondary AML) randomized to receive either 600 mg or 300 mg of tipifarnib orally twice daily on days 1-21 or days 1-7 and 15-21, repeated every 28 days (4 treatment regimens). Responses were seen in all regimens, with overall response rate (CR + CRi + PR) highest (20%) among patients receiving tipifarnib 300 mg twice daily on days 1-21. Toxicities were acceptable. Unless predictors of response to tipifarnib are identified, further study as a single agent in this population is unwarranted.

Citing Articles

Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG.

Othus M, Thomas I, Wang X, Ariti C, Mehta P, Sydenham M Leuk Lymphoma. 2022; 64(1):250-252.

PMID: 36226777 PMC: 10662133. DOI: 10.1080/10428194.2022.2131416.

The role of cholesterol metabolism in leukemia.

Zhao L, Zhan H, Jiang X, Li Y, Zeng H Blood Sci. 2022; 1(1):44-49.

PMID: 35402792 PMC: 8975102. DOI: 10.1097/BS9.0000000000000016.

Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial.

Luger S, Wang V, Rowe J, Litzow M, Paietta E, Ketterling R Leuk Res. 2021; 111:106736.

PMID: 34773794 PMC: 8643322. DOI: 10.1016/j.leukres.2021.106736.

Advantages of multi-arm non-randomised sequentially allocated cohort designs for Phase II oncology trials.

Mossop H, Grayling M, Gallagher F, Welsh S, Stewart G, Wason J Br J Cancer. 2021; 126(2):204-210.

PMID: 34750494 PMC: 8770479. DOI: 10.1038/s41416-021-01613-5.

Benchmarking treatment effects for patients over 70 with acute myeloid leukemia: A systematic review and meta-analysis.

Reljic T, Sehovic M, Lancet J, Kim J, Al Ali N, Djulbegovic B J Geriatr Oncol. 2020; 11(8):1293-1308.

PMID: 32665186 PMC: 7864384. DOI: 10.1016/j.jgo.2020.06.019.

References

Harousseau J, Martinelli G, Jedrzejczak W, Brandwein J, Bordessoule D, Masszi T . A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. Blood. 2009; 114(6):1166-73. DOI: 10.1182/blood-2009-01-198093. View

Estey E, Thall P, Giles F, Wang X, Cortes J, Beran M . Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine.... Blood. 2002; 99(12):4343-9. DOI: 10.1182/blood.v99.12.4343. View

Lancet J, Gojo I, Gotlib J, Feldman E, Greer J, Liesveld J . A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood. 2006; 109(4):1387-94. PMC: 1794070. DOI: 10.1182/blood-2006-04-014357. View

Amadori S, Suciu S, Stasi R, Willemze R, Mandelli F, Selleslag D . Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and.... Leukemia. 2005; 19(10):1768-73. DOI: 10.1038/sj.leu.2403901. View

Appelbaum F, Gundacker H, Head D, Slovak M, Willman C, Godwin J . Age and acute myeloid leukemia. Blood. 2006; 107(9):3481-5. PMC: 1895766. DOI: 10.1182/blood-2005-09-3724. View

Karp J, Lancet J, Kaufmann S, End D, Wright J, Bol K . Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood. 2001; 97(11):3361-9. DOI: 10.1182/blood.v97.11.3361. View

Cashen A, Schiller G, ODonnell M, Dipersio J . Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol. 2009; 28(4):556-61. DOI: 10.1200/JCO.2009.23.9178. View

Cheson B, Bennett J, Kopecky K, Buchner T, Willman C, Estey E . Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003; 21(24):4642-9. DOI: 10.1200/JCO.2003.04.036. View

Fenaux P, Raza A, Mufti G, Aul C, Germing U, Kantarjian H . A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. Blood. 2007; 109(10):4158-63. DOI: 10.1182/blood-2006-07-035725. View

10.

Kurzrock R, Kantarjian H, Cortes J, Singhania N, Thomas D, Wilson E . Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood. 2003; 102(13):4527-34. DOI: 10.1182/blood-2002-11-3359. View

11.

Kirschbaum M, Synold T, Stein A, Tuscano J, Zain J, Popplewell L . A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia. Leukemia. 2011; 25(10):1543-7. PMC: 3165084. DOI: 10.1038/leu.2011.124. View

12.

Kantarjian H, Thomas X, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J . Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012; 30(21):2670-7. PMC: 4874148. DOI: 10.1200/JCO.2011.38.9429. View

13.

Reuter C, Morgan M, Bergmann L . Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?. Blood. 2000; 96(5):1655-69. View

14.

Burnett A, Milligan D, Prentice A, Goldstone A, McMullin M, Hills R . A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007; 109(6):1114-24. DOI: 10.1002/cncr.22496. View

15.

Menzin J, Lang K, Earle C, Kerney D, Mallick R . The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med. 2002; 162(14):1597-603. DOI: 10.1001/archinte.162.14.1597. View

16.

Lowenberg B, Zittoun R, KERKHOFS H, Jehn U, Abels J, Debusscher L . On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol. 1989; 7(9):1268-74. DOI: 10.1200/JCO.1989.7.9.1268. View

17.

Tilly H, Castaigne S, Bordessoule D, Casassus P, Le Prise P, Tertian G . Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol. 1990; 8(2):272-9. DOI: 10.1200/JCO.1990.8.2.272. View

18.

Rowinsky E, Windle J, Von Hoff D . Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. J Clin Oncol. 1999; 17(11):3631-52. DOI: 10.1200/JCO.1999.17.11.3631. View

19.

Fenaux P, Mufti G, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U . Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2009; 28(4):562-9. DOI: 10.1200/JCO.2009.23.8329. View

20.

Harousseau J, Lancet J, Reiffers J, Lowenberg B, Thomas X, Huguet F . A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia. Blood. 2007; 109(12):5151-6. DOI: 10.1182/blood-2006-09-046144. View